Focused On-demand Library for RNA-binding protein Nova-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UNW9

UPID:

NOVA2_HUMAN

Alternative names:

Astrocytic NOVA1-like RNA-binding protein; Neuro-oncological ventral antigen 2

Alternative UPACC:

Q9UNW9; O43267; Q9UEA1

Background:

RNA-binding protein Nova-2, also known as Neuro-oncological ventral antigen 2, plays a pivotal role in the regulation of alternative splicing in neurons. It specifically binds to the sequences 5'-YCAY-3', influencing exon inclusion or exclusion. This protein's unique ability to regulate splicing events of axon guidance related genes is crucial for the development of the central nervous system, affecting neural networks wiring and synapse formation.

Therapeutic significance:

Nova-2 is linked to a neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, characterized by intellectual disability and motor coordination issues. Understanding the role of RNA-binding protein Nova-2 could open doors to potential therapeutic strategies for these conditions.